KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Intangibles (2020 - 2025)

Recursion Pharmaceuticals' Intangibles history spans 6 years, with the latest figure at $309.9 million for Q4 2025.

  • For Q4 2025, Intangibles fell 7.73% year-over-year to $309.9 million; the TTM value through Dec 2025 reached $309.9 million, down 7.73%, while the annual FY2025 figure was $309.9 million, 7.73% down from the prior year.
  • Intangibles reached $309.9 million in Q4 2025 per RXRX's latest filing, down from $322.3 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $341.3 million in Q2 2025 to a low of $1.2 million in Q2 2022.
  • Average Intangibles over 5 years is $110.4 million, with a median of $36.4 million recorded in 2023.
  • Peak YoY movement for Intangibles: fell 18.0% in 2021, then skyrocketed 3367.72% in 2023.
  • A 5-year view of Intangibles shows it stood at $1.4 million in 2021, then fell by 5.7% to $1.3 million in 2022, then surged by 2690.43% to $36.4 million in 2023, then skyrocketed by 821.59% to $335.9 million in 2024, then dropped by 7.73% to $309.9 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Intangibles are $309.9 million (Q4 2025), $322.3 million (Q3 2025), and $341.3 million (Q2 2025).